CMS News is Good for Troubled Markets
There was probably no group more relieved than the makers of implantable cardioverter defibrillators (ICDs) to see the Centers for Medicaid and Medicare Services (CMS) in August drastically modify its proposal to slash hospital reimbursement. The change is as a result of effective lobbying from the medical device community as well as the hospital industry, and is welcome news to all high-end device makers.
You may also be interested in...
The goal of developing a nationwide system of electronic healthcare records (EHRs) for most all Americans is moving at a slower pace than some would like. But now, a group of large and influential employers has entered the picture with a plan that seems poised to change the speed and leadership of the endeavor.
The clinical trials MADIT II and SCD-HeFT definitively proved the benefit of ICDs for preventing the risk of sudden cardiac death and paved the way for reimbursement. But now that the excitement has died down, the confusion has set in. Clinicians aren't entirely sure in which real-world patients to implant devices. The debate about the proper methods of risk stratifying patients for ICD implantation rages on.
The perception that product liability is primarily something that only large, well-established companies need to worry about-say product liability experts, is a belief that small companies in particular hold at their peril.